MedTrace Logo

Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers

NCT05120947 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.

Conditions

  • Resectable Head and Neck Squamous Cell Carcinoma

Interventions

RADIATION

42 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 4.2 Gy.

RADIATION

39 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 4.875 Gy.

RADIATION

32.5 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 6.5 Gy.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Musaddiq Awan, MD · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2025-03-06
Completion
2025-11-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120947 on ClinicalTrials.gov